School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
Lung Cancer. 2010 Oct;70(1):1-6. doi: 10.1016/j.lungcan.2010.05.016. Epub 2010 Jun 11.
Imaging of malignant pleural mesothelioma (MPM) poses many challenges for imaging specialists and clinicians due to the anatomic location and unique growth pattern of this tumor. Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management. Imaging-based studies presented at the 9th International Conference of the International Mesothelioma Interest Group (IMIG) in October 2008 sought to further define the current practice and future potential of imaging for the mesothelioma patient. The Imaging Session was dominated by presentations that addressed the use of fluorodeoxyglucose positron emission tomography (FDG-PET), a clear indication of the expanding role of this modality. These uses included FDG-PET imaging at the point of diagnosis, in prognostication, and in the assessment of response to chemotherapy. Often FDG-PET studies were combined with computed tomography (CT) scans in an attempt to overcome limitations associated with either imaging modality alone. At diagnosis, FDG-PET parameters had a high sensitivity and specificity for differentiation of benign from malignant pleural disease. The use of FDG-PET to extract quantitative features from metabolically active tumor volume was shown to be a significant factor in the prediction of patient survival. The prognostic value of FDG-PET was not confounded by prior talc pleurodesis, despite the inflammatory response associated with the procedure. Metabolic response based on FDG-PET was found to be significantly correlated with progression-free survival. CT-based assessment of mesothelioma was determined to be inconsistent with spherical-model-based criteria so that changes in tumor area, a presumably more complete assessment of tumor burden, exhibited a 46% concordance rate with changes in linear measurements.
恶性胸膜间皮瘤(MPM)的影像学表现给影像专家和临床医生带来了诸多挑战,这主要是由于该肿瘤的解剖位置和独特的生长方式所致。然而,MPM 的影像学检查在诊断、预后、预测或评估治疗反应以及监测积极手术治疗后的疾病复发方面发挥着至关重要的作用。在 2008 年 10 月举行的第 9 届国际间皮瘤兴趣小组(IMIG)国际会议上提交的影像学研究旨在进一步明确影像学在间皮瘤患者中的当前应用和未来潜力。影像学专场主要介绍了氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)的应用,这清楚地表明了该方法的应用范围不断扩大。这些应用包括在诊断、预后以及评估化疗反应时进行 FDG-PET 成像。通常,FDG-PET 研究与计算机断层扫描(CT)扫描相结合,试图克服任何单一成像方式的局限性。在诊断时,FDG-PET 参数对区分良性和恶性胸膜疾病具有很高的敏感性和特异性。从代谢活跃的肿瘤体积中提取定量特征的 FDG-PET 应用被证明是预测患者生存的重要因素。FDG-PET 的预后价值不受滑石粉胸膜固定术的影响,尽管该手术与炎症反应相关。基于 FDG-PET 的代谢反应与无进展生存期显著相关。基于 CT 的间皮瘤评估与基于球形模型的标准不一致,因此肿瘤面积的变化(推测是对肿瘤负担的更完整评估)与线性测量变化的一致性为 46%。